Clinical trial
CEP-701 for PH-negative Myelofibrosis
NCT00494585 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00494585 |
|---|---|
| Title | CEP-701 for PH-negative Myelofibrosis |
| Official title | Evaluation of CEP-701, an Orally Available JAK2 Tyrosine Kinase Inhibitor, as a Therapy for Patients With Myelofibrosis |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Cephalon Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelofibrosis |
| Intervention type | Drug |
| Interventions | CEP-701 |
| Enrollment | 27 |
| Start date | Jun 1, 2007 |
| Primary completion | May 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Jun 29, 2007 |
| Last update posted | Jun 25, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: